Did Capital Allocation Change With the CEO? A Berkshire Hathaway Case Study

Berkshire closed two acquisitions worth about $16.2 billion after Greg Abel became CEO. Agreement dates and the buyback rule show what changed at the handoff.

In this article

Berkshire Hathaway closed two acquisitions worth roughly $16.2 billion in Greg Abel’s first nine months as CEO. One of them, OxyChem, accounted for 58% of that amount and was already under contract when he took office. An investor using closing dates alone would attribute both commitments to the new leadership period. The agreement dates support that conclusion for only one deal. Berkshire’s appointment notice · Third-quarter 2026 filing, Note 2

Give each acquisition two dates

Berkshire named Abel as Buffett’s successor in May 2025, effective January 1, 2026. Buffett remained chairman. The interval between the announcement and the effective date matters for OxyChem. Investors knew who the next CEO would be when Berkshire signed the deal, while Buffett still held the job. Board decision

AcquisitionAgreement signedClosedCash consideration in the Q3 2026 filingWhat the dates establish
Occidental’s chemicals business, OxyChemOctober 1, 2025January 2, 2026About $9.4bn including adjustmentsCommitment under Buffett, completion under Abel
Taylor Morrison Home CorporationMay 31, 2026July 24, 2026About $6.8bnBoth events occurred during Abel’s tenure

For a review of businesses acquired in the first nine months, both rows belong. For a review of the acquisition agreements the company entered during that tenure, retain Taylor Morrison and record OxyChem as an inherited commitment. The 58% comes from dividing $9.4 billion by the $16.2 billion combined consideration for these two transactions. It is a share of this specific pair. The filings establish corporate actions and dates. They do not apportion personal credit for negotiating either transaction. Berkshire’s acquisition note

Read the rule governing the buyback

Berkshire’s 2025 filing allowed repurchases when Buffett, then chairman and CEO, judged the shares to trade below a conservative estimate of intrinsic value. It also barred purchases that would take consolidated cash, cash equivalents and US Treasury bills below $30 billion. Berkshire bought back no shares in the nine months ended September 30, 2025. Third-quarter 2025 filing, shareholders’ equity note

One year later, the same valuation test and liquidity floor applied. The decision now sat with the CEO after consultation with the chairman. Execution changed markedly. Berkshire acquired $14.4 billion of treasury stock in the nine months ended September 30, 2026, including September purchases settled in October. An analyst reconciling the cash-flow statement will find $13.757 billion paid for treasury stock in those nine months. Use the acquisition figure for purchase decisions and the cash figure for financing cash flow. Third-quarter 2026 filing, cash flows and Financial Condition

A shift from zero to $14.4 billion is evidence that Berkshire acted differently under the rule. Proving the company lowered its valuation hurdle would require a changed policy or a disclosed change to its estimate of intrinsic value. The repurchase total supplies neither. A further question, how much a buyback reduced the share count, takes another calculation.

What belongs in the investment memo

Buffett’s final annual letter described a continuing preference for business ownership, through controlled companies and marketable equities. Abel’s first letter likewise favored productive businesses over Treasury holdings. He identified expansion of existing businesses, acquisitions, equity investments and repurchases as uses of capital assessed against long-term intrinsic value per share. The letters support continuity in the stated objective. They give no fixed percentage to allocate to those competing uses. Buffett’s 2024 letter · Abel’s 2025 letter

For Berkshire through September 2026, the defensible revision to a company investment memo is specific. Berkshire signed a large homebuilder acquisition during Abel’s tenure and resumed material repurchases under a familiar valuation test. The chairman’s consultation role is explicit. Charging the OxyChem agreement to Abel’s tenure, or inferring a permanently higher buyback budget from nine months of purchases, would change the investment thesis beyond what shareholders were told.